McGrew Matthew sold $7.0M of DHR

McGrew Matthew (Executive Vice President) sold 29,754 shares of DANAHER CORP /DE/ (DHR) at an average of $235.74 ($235.35–$236.09, $7.01M total) across 2 trades on 2026-10-28.

Original reporting
SEC EDGAR · McGrew Matthew
Published Oct 29, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DHR
Neutral
medium confidence
Mentioned
$DHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRNeutralLow
01

Why it matters

This is a primary-source disclosure of an executive’s open-market sale. It may influence short-term sentiment, but it does not provide new fundamentals or forward-looking guidance.

02

Market read

Traders may monitor for follow-on insider activity or correlate with other news, but the standalone insider sale is typically a low-conviction signal.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty, but the article still lacks any accompanying company-specific catalyst.

Relevance 6/10Novelty 6/10Timing: filed 2026-10-29, trades dated 2026-10-28

Background

The article summarizes an SEC Form 4 insider transaction for Danaher, identifying the seller, role, trade type, dates, share count, and value.

Company-level read

Ticker impact

$DHRNeutralMedium confidence
Context

Danaher insider Form 4 shows EVP McGrew Matthew sold 29,754 shares in open-market trades for about $7.01M on 2026-10-28.

Expected impact

Likely limited near-term impact, with traders treating it as routine insider selling unless other company-specific news emerges.

Evidence & confidence

The article is a primary SEC Form 4 disclosure, but it does not include guidance, operational changes, or a 10b5-1 plan; insider sales alone are often non-informational.

Market effects

Minimal, as this is a single-company insider transaction without sector-wide signal.

None expected beyond normal US large-cap sentiment flow.

None expected.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be noise rather than bearish information.

Key entities

  • Danaher Corp /DE/

    US-listed company whose executive sold shares, disclosed via SEC Form 4.

  • McGrew Matthew

    Executive Vice President who sold 29,754 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.